Document is current
Any future updates will be listed below
-
Authors
Li, Xinxing https://orcid.org/0009-0007-9586-327X
Liu, Tao
Bacchiocchi, Antonella
Li, Mengxing
Cheng, Wen https://orcid.org/0000-0001-9587-3813
Wittkop, Tobias
Mendez, Fernando L https://orcid.org/0000-0002-0879-3813
Wang, Yingyu https://orcid.org/0000-0002-6662-4321
Tang, Paul
Yao, Qianqian https://orcid.org/0000-0003-2349-9994
Bosenberg, Marcus W
Sznol, Mario
Yan, Qin https://orcid.org/0000-0003-4077-453X
Faham, Malek
Weng, Li https://orcid.org/0009-0000-6080-7488
Halaban, Ruth https://orcid.org/0000-0001-8451-1964
Jin, Hai https://orcid.org/0000-0003-0430-2834
Hu, Zhiqian https://orcid.org/0000-0002-3973-6280
-
Funding
Funding for this research was provided by:
Shanghai Natural Science Foundation (21ZR1458200)
Tongji Hospital (2021)
Tongji Hospital (ITJ(ZD)2104)
HHS | National Institutes of Health (NCI P50CA121974)
- License Information
-
More Information
Article History
Received: 22 January 2024
Revised: 6 July 2024
Accepted: 16 July 2024
First Online: 20 August 2024
Disclosure and competing interests statement
: QQY is an employee of Shanghai YunSheng Medical Laboratory Co., Ltd. LW, PT, FM, YYW, TW, and MF are employees or consultant of AccuraGen Inc. QY received research funding and speaker fee from AstraZeneca and is a Scientific Advisory Board member of AccuraGen, Inc. MWB received research funding from AstraZeneca. MS disclosed the following: stock options: Actym, Adaptive Biotechnologies, Amphivena, Asher, Evolveimmune, Intensity, Nextcure, Normunity, Oncohost, Thetis; Stock: Johnson and Johnson, Glaxo-Smith Kline; consulting fees: Adagene, Adaptimmune, Agenus, Alkermes, Alligator, Anaptys, Asher, Astra Zeneca, Biond, Biontech, Boston Pharmaceuticals, Bristol-Myers, Dragonfly, Evaxion, Evolveimmune, Genentech-Roche, Gilead, Glaxo Smith Kline, Ichnos, Idera, Immunocore, Incyte, Innate pharma, Iovance, iTEOS, Jazz Pharmaceuticals, Kadmon-Sanofi, Kanaph, Merck, Molecular Partners, Nextcure, Nimbus, Normunity, Numab, Ocellaris-Lilly, Oncohost, Ontario Institute for Cancer Research, Partner Therapeutics, Pfizer, Pierre-Fabre, PIO Therapeutics, Pliant, Regeneron, Rootpath, Rubius, Sapience, Simcha, Stcube, Sumitomo, Targovax, Teva, Turnstone, Verastem, Xilio, all these companies are unrelated to this study. Other authors have no conflict of interest to declare.
